Literature DB >> 19857723

CTX-M and TEM as predominant types of extended spectrum beta-lactamases among Serratia marcescens isolated from solid organ recipients.

A Mlynarczyk1, K Szymanek, A Sawicka-Grzelak, J Pazik, T Buczkowska, M Durlik, B Lagiewska, M Pacholczyk, A Chmura, L Paczek, G Mlynarczyk.   

Abstract

BACKGROUND: Serratia marcescens is an important pathogen in hospital infections since organisms resistant to multiple antimicrobials pose a special threat particularly among transplant patients. The aim of this work was to assess the number of strains producing beta-lactamases with extended spectrum (ESBL) among S. marcescens isolated from our patients.
MATERIALS AND METHODS: We investigated S. marcescens isolated from 2005 to 2008 for ESBL. The phenotype methods were applied and additionally we chose strains for polymerase chain reactions using primers for the most popular types of ESBL.
RESULTS: Over the investigated time, 257 patients were infected with S. marcescens with 188 (73%) displaying an ESBL-positive phenotype. A Molecular analysis showed that most of them produced both CTX-M and TEM beta-lactamases. In the last year, the percentage of ESBL-producing strains decreased, but also in the last year, we isolated S. marcescens resistant to carbapenems from three patients.
CONCLUSIONS: The CTX-M type of ESBL predominated among ESBLs produced by strains of S. marcescens. The appearance of strains resistant to carbapenems is alarming.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19857723     DOI: 10.1016/j.transproceed.2009.08.011

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  Serratia infections in a general hospital: characteristics and outcomes.

Authors:  G Samonis; E K Vouloumanou; M Christofaki; D Dimopoulou; S Maraki; E Triantafyllou; D P Kofteridis; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-10       Impact factor: 3.267

Review 2.  Serratia infections: from military experiments to current practice.

Authors:  Steven D Mahlen
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.